Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode

Schizophrenia Research
Diana O PerkinsHGDH Research Group

Abstract

Many patients recovering from a first psychotic episode will discontinue medication against medical advice, even before a 1-year treatment course is completed. Factors associated with treatment adherence in patients with chronic schizophrenia include beliefs about severity of illness and need for treatment, treatment with typical versus atypical antipsychotic and medication side effects. In this 2-year prospective study of 254 patients recovering from a first episode of schizophrenia, schizophreniform, or schizoaffective disorder we examined the relationship between antipsychotic medication non-adherence and patient beliefs about: need for treatment, antipsychotic medication benefits, and negative aspects of antipsychotic medication treatment. We also examined the relationship between medication non-adherence and treatment with either haloperidol or olanzapine, and objective measures of symptom response and side effects. The likelihood of becoming medication non-adherent for 1 week or longer was greater in subjects whose belief in need for treatment was less (HR=1.75, 95% CI 1.16, 2.65, p=0.0077) or who believed medications were of low benefit (HR=2.88, 95 CI 1.79-4.65, p<0.0001). Subjects randomized to haloperidol were more li...Continue Reading

Citations

Jun 11, 2014·BMC Psychiatry·Maya PatelRachel Upthegrove
Sep 15, 2009·Primary Care Companion to the Journal of Clinical Psychiatry·Prakash S MasandJohn M Kane
Jul 26, 2008·Current Psychiatry Reports·Richard J Drake
Jul 17, 2008·Current Psychiatry Reports·William M Glazer, Mathew J Byerly
May 14, 2008·The Australian and New Zealand Journal of Psychiatry·Christine Rummel-KlugeWerner Kissling
Mar 13, 2012·Journal of Affective Disorders·Amal Abdel-BakiAshok Malla
Mar 2, 2012·Psychiatry Research·Katherine A StegerAshok Malla
Mar 6, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Wolfgang GaebelUNKNOWN EUFEST Study Group
Mar 27, 2009·Schizophrenia Research·Martin LambertBenno G Schimmelmann
Mar 3, 2009·L'Encéphale·A CharpentierP Thomas
Apr 30, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Borah KimKi Hwan Yook
Aug 28, 2007·The Psychiatric Clinics of North America·Peter J WeidenMichael Grody
Nov 1, 2015·Psychiatry Research·Deena AshoorianRhonda Clifford
Feb 19, 2009·Journal of Advanced Nursing·Terence V McCannSai Lu
Mar 22, 2008·Journal of Clinical Psychology·Sheri L Johnson, Daniel Fulford
Nov 1, 2008·Early Intervention in Psychiatry·Matthew LargeAnthony Harris
Nov 1, 2008·Early Intervention in Psychiatry·Salvatore De MasiGiovanni De Girolamo
Feb 1, 2009·Early Intervention in Psychiatry·Phuong Le QuachMerete Nordentoft
Mar 5, 2010·Early Intervention in Psychiatry·Jeff C HuffmanRobert J Birnbaum
Jun 30, 2010·Journal of Psychiatric and Mental Health Nursing·C BeseniusP Nolan
May 26, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Pál CzoborJan Volavka
Apr 21, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Sung-Wan KimYoung-Myo Jae

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here